Wave Life Sciences Ltd. (WVE)
| Market Cap | 1.24B +25.6% |
| Revenue (ttm) | 71.80M -31.6% |
| Net Income | -183.59M |
| EPS | -1.03 |
| Shares Out | 192.40M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,642,305 |
| Open | 6.15 |
| Previous Close | 6.19 |
| Day's Range | 6.02 - 6.45 |
| 52-Week Range | 5.02 - 21.73 |
| Beta | -1.32 |
| Analysts | Strong Buy |
| Price Target | 21.94 (+241.75%) |
| Earnings Date | Apr 28, 2026 |
About WVE
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s medicines platform, PRISM combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a GalNAc-conjugated RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; WVE-007, a GalNAc... [Read more]
Financial Performance
In 2025, Wave Life Sciences's revenue was $42.73 million, a decrease of -60.55% compared to the previous year's $108.30 million. Losses were -$204.38 million, 110.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for WVE stock is "Strong Buy." The 12-month stock price target is $21.94, which is an increase of 241.75% from the latest price.
News
Wave Life Sciences Transcript: RBC Capital Markets Global Healthcare Conference 2026
Key advances include progress in siRNA and RNA editing platforms, with promising clinical data for obesity and AATD. Monthly dosing regimens and biomarker-driven regulatory strategies are being pursued, while new studies target high BMI and cardiometabolic endpoints.
Wave Life Sciences price target raised to $14 from $13 at Wells Fargo
Wells Fargo raised the firm’s price target on Wave Life Sciences (WVE) to $14 from $13 and keeps an Overweight rating on the shares. The firm notes the WVE-007 update…
Wave Life Sciences Supports AlphaDetect to Accelerate Detection of Alpha-1
The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease. DURHAM, N.C.
Wave Life Sciences price target lowered to $13 from $18 at H.C. Wainwright
H.C. Wainwright lowered the firm’s price target on Wave Life Sciences (WVE) to $13 from $18 and keeps a Buy rating on the shares. WVE-006’s readout at the American Thoracic…
Wave Life Sciences Transcript: Study update
RestorAATion-2 phase I/II data show WVE-006 achieves robust, durable Z-AAT reduction and wild-type M-AAT restoration, mimicking the protective MZ phenotype in PiZZ AATD. The therapy is safe, well-tolerated, and supports convenient monthly dosing, with dynamic AAT responses during inflammation.
Wave Life Sciences Press release: Study update
Wave Life Sciences issued a press release on May 18, 2026, disclosing material business information to investors.
Wave Life Sciences Slides: Study update
Wave Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Wave Life Sciences announces updated data from RestorAATion-2 trial of WVE-006
Wave Life Sciences (WVE) announced updated data from the ongoing RestorAATion-2 trial of WVE-006, its investigational, GalNAc-conjugated, subcutaneously delivered RNA editing oligonucleotide for alpha...
Wave Life Sciences Announces Positive Update on RestorAATion-2 Trial: WVE-006 (GalNAc-RNA Editing) Achieves MZ-Like Phenotype Across Both Biweekly and Monthly Dosing
Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with mo...
Wave Life Sciences to Present at 2026 RBC Capital Markets Global Healthcare Conference
CAMBRIDGE, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd.
Wave Life Sciences Proxy statement: Proxy filing
Wave Life Sciences filed a proxy statement on May 7, 2026, providing details for shareholder voting and corporate governance matters.
Wave Life Sciences price target lowered to $24 from $30 at Citi
Citi analyst Samantha Semenkow lowered the firm’s price target on Wave Life Sciences (WVE) to $24 from $30 and keeps a Buy rating on the shares.
Wave Life Sciences Proxy statement: Proxy filing
Wave Life Sciences filed a proxy statement on May 1, 2026, providing details for shareholder voting and corporate governance matters.
Wave Life Sciences price target lowered to $43 from $52 at Canaccord
Canaccord lowered the firm’s price target on Wave Life Sciences (WVE) to $43 from $52 and keeps a Buy rating on the shares. The firm said headed into the next…
Wave Life Sciences price target lowered to $19 from $21 at BofA
BofA analyst Alec Stranahan lowered the firm’s price target on Wave Life Sciences (WVE) to $19 from $21 and keeps a Buy rating on the shares. Following the Q1 report,…
Wave Life Sciences assumed with a Buy at Truist
Truist assumed coverage of Wave Life Sciences (WVE) with a Buy rating and price target of $15, down from $50. The firm says the reduced price target reflects higher risk…
Wave Life Sciences price target lowered to $36 from $39 at Clear Street
Clear Street lowered the firm’s price target on Wave Life Sciences (WVE) to $36 from $39 and keeps a Buy rating on the shares following the Q1 report. The firm…
Wave Life Sciences Earnings Call Transcript: Q1 2026
Lead programs for obesity and AATD advanced with strong clinical data, including significant visceral fat loss and dynamic AAT restoration. Revenue surged year-over-year, cash runway extends into 2028, and multiple pivotal trials and regulatory milestones are expected in 2026.
Wave Life Sciences Earnings release: Q1 2026
Wave Life Sciences released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Wave Life Sciences Quarterly report: Q1 2026
Wave Life Sciences has published its Q1 2026 quarterly earnings report on April 28, 2026.
Wave Life Sciences reports Q1 EPS (13c), consensus (31c)
Reports Q1 revenue $38.25M, consensus $7.92M. “We’re accelerating WVE-007 to the next stages of development following the improvements in body composition already observed in the Phase 1 portion of ou...
Wave Life Sciences Reports First Quarter 2026 Financial Results and Provides Business Update
With recent FDA acceptance of the Phase 2a multidose portion of INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with higher BMI, with and without type 2 diabetes, this portion of the tri...
Wave Life Sciences First Quarter 2026 Financial Results Scheduled for April 28, 2026
CAMBRIDGE, Mass., April 22, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transfor...
Wave Life Sciences announces hearing on proposed redomicilation
As previously announced, Wave Life Sciences (WVE) is seeking shareholders’ and Singapore High Court approvals in relation to a scheme of arrangement under Section 210 of the Companies Act 1967…
Wave Life Sciences Announces Hearing on Proposed Redomiciliation to the United States
CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- As previously announced, Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of ...